Certis Oncology Solutions Unveils CertisOI Assistant™
Bringing Chatbot Efficiency to Oncology Research Certis Oncology Solutions, a translational science and emerging technology leader in preclinical oncology research, is pleased to announce the commercial launch of CertisOI Assistant™, an innovative chatbot tool designed to enhance the efficiency and effectiveness of cancer research. This cutting-edge research tool leverages artificial... The post Certis Oncology Solutions Unveils CertisOI Assistant™ first appeared on AI-Tech Park.
Editor-Admin
Bringing Chatbot Efficiency to Oncology Research
Certis Oncology Solutions, a translational science and emerging technology leader in preclinical oncology research, is pleased to announce the commercial launch of CertisOI Assistant
, an innovative chatbot tool designed to enhance the efficiency and effectiveness of cancer research. This cutting-edge research tool leverages artificial intelligence/machine learning (AI/ML) and OpenAI’s ChatGPT language model to quickly provide researchers with unparalleled insights into cancer models and drug response, bringing greater precision to early drug development decisions.
The CertisOI Assistant works as a natural language intermediary for accessing the genomic and drug sensitivity characterization data associated with thousands of cancer research models, including Certis’ patient-derived xenograft (PDX) models as well as public cancer cell lines from the Cancer Cell Line Encycolopedia (CCLE). It also leverages the company’s proprietary CertisAI Predictive Oncology Intelligence platform—the first and only validated artificial intelligence/machine learning (AI/ML) platform that predicts therapeutic efficacy by identifying complex gene expression signatures that correlate with drug response. Together, these AI-enabled systems offer users an efficient, data-driven approach to research model selection, biomarker strategy, and in silico validation. By simply asking the CertisOI Assistant, users can convert query results into charts and graphs and download summary and detailed data for sharing.
“The launch of CertisOI Assistant represents an important next step in our mission to realize the promise of precision cancer medicine,” said Peter Ellman, President and CEO of Certis Oncology. “By empowering researchers with the ability to quickly analyze and interpret complex data, we accelerate the process of scientific investigation and ultimately facilitate the development of more effective and personalized cancer treatments.”
The post Certis Oncology Solutions Unveils CertisOI Assistant™ first appeared on AI-Tech Park.
